|
 Bharat Biotech celebrated 30 years of scientific innovation, public health impact, and its continued commitment to protecting lives in India and around the world. Commemorating this significant milestone, the company unveiled a special anniversary logo symbolising its three-decade legacy of excellence and impact.
The logo was unveiled by its founders, Dr. Krishna Ella, executive chairman, and Suchitra Ella, managing director, amid enthusiastic applause from its large workforce at its Genome Valley facility. The celebration marked the beginning of a year-long calendar of initiatives highlighting the company’s journey and reaffirming its focus on advancing global health.
Reflecting on the milestone, Dr. Ella, said, “Thirty years ago, we started Bharat Biotech with a simple but powerful belief, that Indian science can solve global health challenges. Our strength has always been our scientists, our proprietary technologies, and our commitment to innovation with purpose. Every vaccine we developed carries the hard work of teams who believed that affordable healthcare is a right, not a privilege.”
Suchitra Ella, managing director, Bharat Biotech said, “This journey is about people, the researchers in our labs, the partners who trusted us, and the families whose lives have been protected by our vaccines. We built our own intellectual property, our own manufacturing strengths, and our own scientific platforms because we believed India must lead, not follow. As we enter advanced cell and gene therapy, we remain guided by the same mission: science for society.”
From its early breakthrough in developing one of the world’s most affordable recombinant hepatitis B vaccines, Bharat Biotech established itself as a pioneer in accessible vaccine innovation, focused on addressing infectious and neglected diseases that disproportionately affect emerging nations.
It developed and supplied vaccines that form an integral part of national and global immunization programs, including vaccines against Rotavirus, Japanese Encephalitis, Malaria (RTS, S), and Typhoid Conjugate Disease.
A defining milestone in the company’s journey was the development of its indigenous Rotavirus vaccine through an Indo-US public–private partnership, aimed at protecting millions of children from life-threatening diarrheal disease.
The company’s Japanese Encephalitis vaccine significantly strengthened India’s response to a recurring and often fatal seasonal threat. It further advanced global immunisation efforts with the development and introduction of a pioneering Typhoid Conjugate Vaccine (TCV). The company is also advancing MTBVAC, a tuberculosis vaccine candidate, as part of ongoing efforts to address the global TB burden.
During the Covid-19 pandemic, Bharat Biotech demonstrated its scientific agility with the rapid development of Covaxin, India’s first indigenously developed Covid-19 vaccine in collaboration with the Indian Council of Medical Research.
Reinforcing its commitment to scale and next-generation innovation, the company established Sapigen Biologix at the Odisha Biotech Park. Recently, the company stepped into the future with advanced research in cell and gene therapies through Nucelion Therapeutics.
|